Novorapid Innolet (Insulin Aspart)

Insulin Aspart, the active ingredient in Novorapid Innolet, is a rapid‑acting insulin analog presented as a solution for subcutaneous use. It lowers blood glucose by stimulating cellular uptake and inhibiting hepatic glucose production, and is employed to control glycaemia in patients with type 1 and type 2 diabetes mellitus.

GNH USA supplies Novorapid Innolet as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality assurance, cold‑chain logistics and regulatory conformity across global markets.

Novorapid Innolet, a rapid‑acting insulin analog, is indicated for the management of hyperglycaemia in diabetes mellitus.

- Type 1 diabetes mellitus: provides mealtime insulin coverage to reduce post‑prandial glucose excursions. - Type 2 diabetes mellitus: used as part of intensive insulin regimens to achieve glycaemic targets, especially when oral agents are insufficient. - Gestational diabetes mellitus: administered to achieve tight glucose control when diet alone is inadequate, ensuring maternal and fetal health.

Novorapid Innolet may be associated with several adverse reactions, ranging from frequent to rare.

Common Side Effects: - Hypoglycaemia: symptoms such as sweating, tremor, and confusion. - Injection site reactions: redness, swelling, or itching at the injection site. - Weight gain: modest increase in body weight due to improved glucose utilization. - Lipodystrophy: localized changes in subcutaneous fat at injection sites.

Serious or Rare Side Effects: - Severe hypoglycaemia: prolonged loss of consciousness or seizures. - Allergic reactions: urticaria, angioedema, or anaphylaxis. - Lipohypertrophy: accumulation of fatty tissue leading to erratic insulin absorption.

When using Novorapid Innolet, several precautions should be observed to ensure safe and effective therapy. - Blood glucose monitoring: check levels before meals and at bedtime to adjust dose. - Hypoglycaemia risk: educate patients on recognizing and treating low blood sugar promptly. - Renal impairment: use with caution and consider dose reduction in patients with reduced kidney function. - Hepatic impairment: monitor closely as liver disease may affect insulin clearance. - Pregnancy and lactation: consult a healthcare professional before initiating therapy. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake the vial.

Novorapid Innolet can interact with other medicines, affecting its glucose‑lowering action or safety profile.

Major Interactions (Avoid): - Beta‑blockers: may mask hypoglycaemia symptoms, requiring closer monitoring. - Alcohol: can potentiate insulin’s effect, increasing risk of severe hypoglycaemia. - Sulfonylureas or meglitinides: additive glucose‑lowering effect may cause profound hypoglycaemia.

Moderate Interactions (Monitor Closely): - ACE inhibitors and ARBs: may enhance insulin sensitivity, modestly lowering glucose. - Thiazide diuretics: can increase blood glucose, potentially reducing insulin efficacy. - Corticosteroids: raise glucose levels, possibly necessitating dose adjustments.